Last $36.11 USD
Change Today +0.11 / 0.31%
Volume 194.4K
PODD On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

insulet corp (PODD) Snapshot

Open
$36.07
Previous Close
$36.00
Day High
$36.27
Day Low
$35.86
52 Week High
03/21/14 - $51.31
52 Week Low
08/8/14 - $30.04
Market Cap
2.0B
Average Volume 10 Days
309.9K
EPS TTM
$-0.73
Shares Outstanding
55.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INSULET CORP (PODD)

insulet corp (PODD) Related Bloomberg News

View More Bloomberg News

insulet corp (PODD) Related Businessweek News

No Related Businessweek News Found

insulet corp (PODD) Details

Insulet Corporation develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. The company offers OmniPod Insulin Management System (OmniPod System), which consists of the OmniPod, a disposable insulin infusion device that integrates an infusion set, automated cannula insertion, insulin reservoir, drive mechanism, and batteries; and a handheld, wireless personal diabetes manager. It is also involved in the distribution of durable medical equipment, including blood glucose testing supplies, insulin pumps, pump supplies, pharmaceuticals, and other products for the management and treatment of diabetes. The company sells its OmniPod System directly to patients through referrals from healthcare professionals and through patient leads, as well as through third-party distributors. Insulet Corporation was founded in 2000 and is based in Bedford, Massachusetts.

478 Employees
Last Reported Date: 02/28/14
Founded in 2000

insulet corp (PODD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $448.4K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $330.4K
Chief Commercial Officer
Total Annual Compensation: $306.3K
Director of Advanced Technology and Director
Total Annual Compensation: $376.9K
General Counsel and Secretary
Total Annual Compensation: $265.0K
Compensation as of Fiscal Year 2013.

insulet corp (PODD) Key Developments

Insulet Corporation and DexCom to Develop CGM-Integrated Diabetes Manager

Insulet Corporation and DexCom, Inc. have agreed to develop a CGM-integrated personal diabetes manager. This will allow information from Dexcom's 5th generation CGM system to be identified, received and displayed on Insulet's new Bluetooth-enabled Personal Diabetes Manager. This project expands upon the initial agreement announced in June to enable the Dexcom mobile app platform to integrate data from Insulet's OmniPod System. That platform to enable glucose and pump data to be displayed on a smartphone.

Insulet Appoints Timothy J. Scannell to Board of Directors

Insulet Corporation announced the appointment of Timothy J. Scannell to the company's board of directors. Mr. Scannell currently serves as Group President, MedSurg & Neurotechnology at Stryker Corporation. Mr. Scannell's general management responsibilities at Stryker date back to 2001, and since 2008 he has served as group president overseeing multiple global businesses including Neurotechnology, Endoscopy, Medical, Sustainability Solutions, Instruments and CMF. Mr. Scannell served as General Manager and President of Stryker Spine from 2003 to 2008 and led all functions of the business.

Insulet Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter and Full Year of 2014 and Provides Interest Expense Guidance for the Fourth Quarter of 2014

Insulet Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $72.013 million against $60.092 million a year ago. Operating loss was $5.280 million against $5.822 million a year ago. Loss before income taxes was $29.059 million against $10.401 million a year ago. Net loss was $29.111 million or $0.53 per basic and diluted share against $10.519 million or $0.20 per basic and diluted share a year ago. Excluding the impact of the settlement and legal costs, the company would have reported an operating profit of $1.7 million in the quarter. Excluding the impact of the extinguishment of debt and the settlement and legal costs, the company's net loss was $3.2 million or approximately $0.06 per share. For the six months, the company reported revenue of $141.174 million against $117.448 million a year ago. Operating loss was $7.166 million against $12.028 million a year ago. Loss before income taxes was $35.138 million against $20.935 million a year ago. Net loss was $35.255 million or $0.64 per basic and diluted share against $21.184 million or $0.40 per basic and diluted share a year ago. For the third quarter of 2014, the company expects that revenue will be in the range of $73 to $77 million. Going forward, the company expects to record total interest expense the third quarter of $3 million comprised of $1 million in cash interest expense and $2 million in noncash interest expense. While on the consolidated basis, gross margins continue to be impacted slightly by pricing product mix within the company’s neighborhood subsidiary, the company is confident that it will see continued gross margin expansion of approximately 200 to 300 basis points per quarter for each of the third and fourth quarters of 2014. For the fourth quarter, the company expects to record total interest expense for the fourth quarter of $3 million comprised of $1 million in cash interest expense and $2 million in noncash interest expense. While on the consolidated basis, gross margins continue to be impacted slightly by pricing product mix within the company’s neighborhood subsidiary, the company is confident that it will see continued gross margin expansion of approximately 200 to 300 basis points per quarter for each of the third and fourth quarters of 2014. For the year ending December 31, 2014, the company updated its estimate of revenue to be in the range of $290 to $300 million. The company adjusted the midpoint of 2014 guidance down approximately 3%, reflecting a payor issue that is delaying new patient starts due to changes in the payor's general pump reimbursement policies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PODD:US $36.11 USD +0.11

PODD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $117.17 USD +0.69
DexCom Inc $44.20 USD -0.08
Smiths Group PLC 1,316 GBp +2.00
Tandem Diabetes Care Inc $14.15 USD +0.10
Unilife Corp $2.55 USD +0.08
View Industry Companies
 

Industry Analysis

PODD

Industry Average

Valuation PODD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.4x
Price/Book 25.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSULET CORP, please visit www.insulet.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.